PhRMA Deal Intact As Senate Health Reform Bill Enters Home Stretch
Executive Summary
The $80 billion deal struck last spring between the White House, Senate Finance Committee Chairman Max Baucus, D-Mont., and the Pharmaceutical Research and Manufacturers of America remained in force as the full Senate moved toward the end of its third week of debating the bill
You may also be interested in...
With Some Rx Tweaks, Senate Bill Moves To Conference With House
The Senate health care reform bill that passed the chamber Dec. 24 and now will go to a conference committee, where differences with the House bill will be ironed out, includes a number of changes introduced as an amendment to the original bill
With Some Rx Tweaks, Senate Bill Moves To Conference With House
The Senate health care reform bill that passed the chamber Dec. 24 and now will go to a conference committee, where differences with the House bill will be ironed out, includes a number of changes introduced as an amendment to the original bill
Killing Part D Rebates For Duals Could Cost Pharma Another $12 Billion
As health care reform approaches a House-Senate conference, there is speculation that pharma will commit more money in order to keep the door closed on broader rebates.